Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics


Achieve Life Sciences, Inc. (ACHV): $8.11

0.19 (+2.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACHV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

ACHV Stock Price Chart Interactive Chart >

Price chart for ACHV

ACHV Price/Volume Stats

Current price $8.11 52-week high $16.10
Prev. close $7.92 52-week low $6.63
Day low $8.00 Volume 75,600
Day high $8.29 Avg. volume 220,145
50-day MA $7.62 Dividend yield N/A
200-day MA $9.56 Market Cap 76.66M

Achieve Life Sciences, Inc. (ACHV) Company Bio


Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.


ACHV Latest News Stream


Event/Time News Detail
Loading, please wait...

ACHV Latest Social Stream


Loading social stream, please wait...

View Full ACHV Social Stream

Latest ACHV News From Around the Web

Below are the latest news stories about Achieve Life Sciences Inc that investors may wish to consider to help them evaluate ACHV as an investment opportunity.

Achieve Life Sciences to Participate in Upcoming Investor Conferences

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021/ Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences.

Yahoo | September 15, 2021

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco (SRNT-E) Conference to be held virtually September 15-17, 2021.

Yahoo | September 14, 2021

Achieve Life Sciences to Participate in Two Upcoming Investor Conferences

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will be participating in two upcoming investor conferences.

Yahoo | September 9, 2021

ACHV: ORCA-2 Fully Enrolled

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter results in a press release and held a conference call after market close on August 12, 2021. The company concurrently filed its Form 10-Q with the SEC. Highlights for the second quarter ended June 30 th and to-date include: ➢

Yahoo | August 16, 2021

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.

Yahoo | August 13, 2021

Read More 'ACHV' Stories Here

ACHV Price Returns

1-mo 12.02%
3-mo -2.17%
6-mo -31.50%
1-year -14.00%
3-year -83.71%
5-year -99.28%
YTD 0.12%
2020 -23.57%
2019 -56.21%
2018 -90.97%
2017 -75.64%
2016 -58.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8077 seconds.